Virax Holdings (ASX:VHL) has changed its name to Prescient Therapeutics and is expected to start trading as (ASX:PTX) on 15th December 2014.
Prescient's flagship asset is its Co-X-Gene anti-cancer technology.
The strength of the technology was confirmed earlier this year by licensing partner Transgene, demonstrating topline results for their Phase 2B clinical trial using Co-X-Gene, conducted under an option with Novartis (NYSE:NVS), in the treatment of Non-Small Cell Lung Cell Cancer.
Novartis is the largest pharmaceutical company in the world with a capitalisation of almost $200 billion, and Transgene’s immunotherapeutic product TG4010, utilizes Virax's Co-X-Gene platform.
Transgene’s activities have also gained the interest of major pharmaceutical company Sanofi (NYSE:SNY) capitalised at over $130 billion.
Sanofi and Transgene have subsequently launched construction of a manufacturing platform for the production of viral vectors, as utilized by Transgene’s immunotherapeutic product.
Medical conditions outside of cancer are also being targeted, including potential veterinary applications.
Virax Holdings (ASX:VHL) has changed its name to Prescient...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.002(7.69%) |
Mkt cap ! $48.11M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $44.61K | 1.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 579398 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2318208 | 1 |
View Market Depth
| Last trade - 15.52pm 29/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |